That came from Phil Daffas, who was the global marketing manager for COH in the early days, when the share price was a few bucks. He meant it as an aspirational target to get PainChek to the point where people call it a mini Cochlear, ie. high earnings growth global business. Of course the businesses have very different products, but there are some similarities in the marketing of an Australian medical technology to the rest of the world, and Phil Daffas has done it before.
PainChek works for adults. Now it is being commercialised, and it will be some time before we know how successful this will be. PainChek Infant is next, and this needs to go through a validation and regulatory approval process just like the adult version.
For me, having Dementia Support Australia and Dementia Training Australia test and endorse the product, makes this a long term hold for me.
Add to My Watchlist
What is My Watchlist?
